MMS Strengthens Leadership in the Area of Project Advisory Services

CANTON, Mich. (12/15/2021) – MMS Holdings Inc., an award-winning, data-focused CRO, announced a restructuring of their consulting services with the launch of a Project Advisory Services Unit to meet the needs of many small to mid-sized organizations in immediate, short and long-term needs for senior-level guidance, specialized consulting, and advisory services.  

With a network of global resources and expertise in all key markets, MMS is committed to helping Sponsors design and execute the most efficient product development programs. MMS Project Advisory Services supports Sponsors’ needs across the entire product lifecycle, from early regulatory development strategy consultations to clinical trial and marketing authorization submissions.  

MMS Project Advisory Services will be led by Jessica Reed, PhD, and includes a growing team of more than 50 expert advisors in regulatory, clinical, nonclinical, compliance and CMC.  In this role, Jessica will continue to build on the Company’s strong reputation in helping customers navigate the complexities of the regulatory environment to accelerate their time to market. 

“Jessica Reed brings a unique blend of strategic leadership skills, including regulatory and project management expertise that is invaluable to biopharmaceutical companies looking for guidance along the entire continuum of the drug development lifecycle,” said Kelly Hill, Executive Vice President, Business Operations and Strategy, MMS. “Our MMS team of strategic advisors have a long history of helping our Sponsors to develop effective strategies and minimize program and project risks along the way. We look forward to continuing this track record under Jessica’s leadership.” 

MMS services portfolio ranges from new chemical entities (NCEs), biologics, biosimilars, well-established substances 505(b)(2) pathway, generic drugs, devices and in-vitro diagnostics. With in-house expertise in drug-device combination products and medical devices, MMS also offers a range of strategic and operational services.  

Learn more about Project Advisory Services here. 

About MMS Holdings

MMS is an award-winning, data-focused CRO that supports the pharmaceutical, biotech, and medical device industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience and a data-driven approach to drug development make MMS a valuable CRO partner, creating compelling submissions that meet rigorous regulatory standards. With a global footprint across four continents, MMS maintains a 97 percent customer satisfaction rating, and the company was named Most Outstanding CRO in the 2019 Biotechnology Awards and Best Global CRO in the 2018 International Life Sciences Awards.

For more information, visit or follow MMS on LinkedIn.

Get in touch with our media team here

Back to MMS News


Read On

FDA Committee Meeting on COVID-19 Vaccines - MMS Holdings

by Samantha Hoopes, PhD, RAC

The US Food and Drug Administration’s (FDA) Vaccines and Related...

Dr. Mike Poole Joins the Board of Scientific Advisors at Top Global CRO MMS Holdings - MMS Holdings

Former Astellas Pharma VP of Biostatistics Joins MMS Holdings

  CANTON, Mich. (November 18, 2021) –  MMS Holdings – a data-focused CRO – announced this week the...